FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 339:398-400 August 6, 1998 Number 6 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Diel, I. J. PubMed Citation

The clinical use of bisphosphonates has increased dramatically during the past five years. The most common indication for these compounds is osteoporosis, but their use in osteolytic bone disease has grown very rapidly. The Food and Drug Administration's approval of pamidronate in 1995 for the treatment of normocalcemic patients with myeloma bone disease and in 1996 for those with osteolytic lesions of metastatic breast cancer was followed by widespread use of pamidronate in patients with tumors that involve bone. Recent clinical studies indicate that pamidronate reduces the frequency of skeletal events in patients with myeloma or breast cancer by approximately . . . [Full Text of this Article]

References

This article has been cited by other articles:

• Talmadge, J. E. (2008). Follistatin as an Inhibitor of Experimental Metastasis. Clin. Cancer Res. 14: 624-626 [Full Text]  
• Takagi, K., Takagi, M., Kanangat, S., Warrington, K. J., Shigemitsu, H., Postlethwaite, A. E. (2005). Modulation of TNF-{alpha} Gene Expression by IFN-{gamma} and Pamidronate in Murine Macrophages: Regulation by STAT1-Dependent Pathways. J. Immunol. 174: 1801-1810 [Abstract] [Full Text]  
• Yaccoby, S., Wezeman, M. J., Henderson, A., Cottler-Fox, M., Yi, Q., Barlogie, B., Epstein, J. (2004). Cancer and the Microenvironment: Myeloma-Osteoclast Interactions as a Model. Cancer Res. 64: 2016-2023 [Abstract] [Full Text]  
• Body, J.-J., Diel, I. J., Lichinitser, M. R., Kreuser, E. D., Dornoff, W., Gorbunova, V. A., Budde, M., Bergstrom, B. (2003). Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases. Ann Oncol 14: 1399-1405 [Abstract] [Full Text]  
• Myoui, A., Nishimura, R., Williams, P. J., Hiraga, T., Tamura, D., Michigami, T., Mundy, G. R., Yoneda, T. (2003). C-Src Tyrosine Kinase Activity Is Associated with Tumor Colonization in Bone and Lung in an Animal Model of Human Breast Cancer Metastasis. Cancer Res. 63: 5028-5033 [Abstract] [Full Text]  
• Powles, T., Paterson, S., Kanis, J. A., McCloskey, E., Ashley, S., Tidy, A., Rosenqvist, K., Smith, I., Ottestad, L., Legault, S., Pajunen, M., Nevantaus, A., Mannisto, E., Suovuori, A., Atula, S., Nevalainen, J., Pylkkanen, L. (2002). Randomized, Placebo-Controlled Trial of Clodronate in Patients With Primary Operable Breast Cancer. JCO 20: 3219-3224 [Abstract] [Full Text]  
• Pearse, R. N., Sordillo, E. M., Yaccoby, S., Wong, B. R., Liau, D. F., Colman, N., Michaeli, J., Epstein, J., Choi, Y. (2001). Multiple myeloma disrupts the TRANCE/ osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression. Proc. Natl. Acad. Sci. USA 10.1073/pnas.201394498v1 [Abstract] [Full Text]  
• Hiraga, T., Williams, P. J., Mundy, G. R., Yoneda, T. (2001). The Bisphosphonate Ibandronate Promotes Apoptosis in MDA-MB-231 Human Breast Cancer Cells in Bone Metastases. Cancer Res. 61: 4418-4424 [Abstract] [Full Text]  
• Michigami, T., Ihara-Watanabe, M., Yamazaki, M., Ozono, K. (2001). Receptor Activator of Nuclear Factor {{kappa}}B Ligand (RANKL) Is a Key Molecule of Osteoclast Formation for Bone Metastasis in a Newly Developed Model of Human Neuroblastoma. Cancer Res. 61: 1637-1644 [Abstract] [Full Text]  
• Dallas, S. L., Garrett, I. R., Oyajobi, B. O., Dallas, M. R., Boyce, B. F., Bauss, F., Radl, J., Mundy, G. R. (1999). Ibandronate Reduces Osteolytic Lesions but not Tumor Burden in a Murine Model of Myeloma Bone Disease. Blood 93: 1697-1706 [Abstract] [Full Text]  
• (1998). Clodronate May Reduce New Breast Cancer Metastases. JWatch Women's Health 1998: 15-15 [Full Text]  
• (1998). Clodronate and Metastatic Breast Cancer. JWatch General 1998: 3-3 [Full Text]  
• Pearse, R. N., Sordillo, E. M., Yaccoby, S., Wong, B. R., Liau, D. F., Colman, N., Michaeli, J., Epstein, J., Choi, Y. (2001). Multiple myeloma disrupts the TRANCE/ osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression. Proc. Natl. Acad. Sci. USA 98: 11581-11586 [Abstract] [Full Text]